For research use only. Not for therapeutic Use.
SLX-4090 is an orally active enterocytic-specific microsomal triglyceride transfer protein (MTP) inhibitor with an IC50 of 8.0 nM. SLX-4090 can be used for the research of dyslipidemia[1].
SLX-4090 inhibits apolipoprotein B (IC50 value 9.6 nM) but not apolipoprotein A1 secretion in Caco-2 cells[1].
SLX-4090 (orally, 30 mg/kg) reduces postprandial lipids by 50% with an ED50 value 7 mg/kg in rats[1].
| Catalog Number | I007487 |
| CAS Number | 913541-47-6 |
| Synonyms | phenyl 6-[[3-methoxy-2-[4-(trifluoromethyl)phenyl]benzoyl]amino]-3,4-dihydro-1H-isoquinoline-2-carboxylate |
| Molecular Formula | C31H25F3N2O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C31H25F3N2O4/c1-39-27-9-5-8-26(28(27)20-10-13-23(14-11-20)31(32,33)34)29(37)35-24-15-12-22-19-36(17-16-21(22)18-24)30(38)40-25-6-3-2-4-7-25/h2-15,18H,16-17,19H2,1H3,(H,35,37) |
| InChIKey | AZUIUVJESCFSLJ-UHFFFAOYSA-N |
| SMILES | COC1=CC=CC(=C1C2=CC=C(C=C2)C(F)(F)F)C(=O)NC3=CC4=C(CN(CC4)C(=O)OC5=CC=CC=C5)C=C3 |
| Reference | [1]. Enoch Kim, et al. A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile. J Pharmacol Exp Ther. 2011 Jun;337(3):775-85. |
